Iqvia price target raised to $300 from $292 at Truist

Truist analyst Jailendra Singh raised the firm’s price target on Iqvia to $300 from $292 and keeps a Buy rating on the shares after its Q2 earnings beat. The company attributed the outperformance in the quarter primarily to better-than-expected Technology & Analytics Solutions segment, or TAS, performance as R&DS continued to perform well, the analyst tells investors in a research note. Truist adds that with TAS driving the outperformance in the quarter and CRO business metrics being stable, investors should feel better about the outlook for Iqvia’s second half.